Orient Europharma, the Regent Pacific Group Limited's commercial strategic partner for Taiwan, Hong Kong, Macau and certain other countries in South East Asia, has received the first deficiency letter from the Taiwan FDA ("TFDA") in respect of its application for FortacinTM and it has completed and sent back its response and supporting documents on 16 June 2020. TFDA has recently approved the DMFs for lidocaine and prilocaine the active pharmaceutical ingredients of FortacinTM. On the assumption that TFDA does not have any further questions/deficiencies, Orient Europharma anticipates approval around January 2021, which would trigger a payment of USD 300,000 (or approximately HKD 2.34 million) to the Group.